SAT0348 Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials

P. Goupille, E. Roussou, G. Burmester, P.J. Mease, A.B. Gottlieb, S. Garces, O. Benichou, D. Adams, W. Xu, P. Nash
2018 Saturday, 16 JUNE 2018   unpublished
Conclusions: As early as wk14, IV GLM demonstrated clinically meaningful improvements in skin PsO irrespective of MTX use and nail PsO. Improvement in DLQI was seen as early as wk8, w/continued improvement at wks14 and 24.
doi:10.1136/annrheumdis-2018-eular.2132 fatcat:rcgdht4mxzbpnllejp56jgq3zm